Secondary Schizophrenia (167 page)

psychotic symptoms/lesion location,

affinity,
88,
89t

Cohen, B. D.,
144

199t

neuroimaging studies,
92

Collaborative Perinatal Project (CPP),

vascular dementia,
200–
1

neuropathological studies,
92–
3

281–
2

Chabot, B.,
359,
360

pathophysiological mechanisms for

Collerton, D.,
25

psychosis in epilepsy,
93–
5

Chapman, F.,
26–
7

cellular/molecular consequences

Columbia University Scale for

Charles Bonnet Syndrome (CBS)

of repeated seizures,
93–
4

Psychopathology in

complex hallucinations,
370–
2

composite model,
95, 95f

Alzheimer’s Disease

complex hallucination sites,
373t
,
cortical dysgenesis hypothesis,
94

(CUSPAD),
209

373–
4

cortical excitation/inhibition

common association, in schizophrenia,

fusiform face area,
373

imbalance,
94–
5

17

superior temporal sulcus face

diffuses brain damage hypothesis,

area,
373

94–
5

comorbid alcoholism,
53–
4

visual word form area,
373

epileptiform disturbance,
93–
4

complex auditory hallucinois,
29–
30

course and outcome,
374

underlying neuropathological/

Composite International Diagnostic

definition,
369–
70

physiological dysfunction,

Interview (CIDI),
122

duration/cessation of hallucinations,

94

374

postlobectomy psychosis,
91–
2,

Computerized International

future research,
375

92t

Diagnostic Interview,
171

computerized tomography (CT)

Davison, K.,
189,
265,
274,
275,
276,

and Huntington’s Disease,
349

brain tumor,
266

334,
340

and traumatic brain injury,
187

Fahr’s Disease,
358,
361

deafferentation syndrome,
372–
3,

and Wilson’s Disease,
341

Huntington’s Disease,
350

374

depression, major,
293

laterality of epileptic focus,
91

and multiple sclerosis,
274

postictal psychosis,
84

default mode network of brain activity,

and velocardiofacial syndrome,
309,

stimulants and psychosis,
133

64

311–
12

ventricular enlargement,
258

Degenhardt, L.,
175

Wilson’s Disease,
339

depth recordings,
82–
3

Deiters cells,
29

COMT gene,
172,
174,
175,

Descheemaeker, M. J.,
329

317–
18

delirium. See
toxic psychosis

Devinsky, O.,
84

Connell, P. H.,
129,
131

delusional disorder,
201

diabetes, and leukodystrophies,
250

conserved noncoding elements

delusional misidentifications,
205,

Diagnostic Interview for Genetic

(CNEs),
297

207t

Studies,
289

copper excretion. See
Wilson’s Disease

delusional parasitosis,
34

Diagnostic Interview Schedule,
122

copy number variations (CNVs),
290,

delusions, and Alzheimer’s Disease,

DIDMOAD (Diabetes Insipidus,

297

205,
207t

Diabetes Mellitus, Optic

Corcoran, C.,
188,
192

dementia

Atrophy, Deafness). See

antipsychotic medications for,
396–
7

Wolfram Disease

core network,
64

diffuses brain damage hypothesis,
94–
5

Cornelius, J.,
22

associated with Fahr’s Disease,
360

diffusion tensor imaging (DTI),
7,
243

corpus callosum (CC)

characteristics of, 181t.
181t
See also
in child with VCFS,
314f

Alzheimer’s Disease

digoxin,
370

increase in child with VCFS,
314

dementia praecox,
4,
289

disconnectivity syndrome,
267

cortical blindness,
232

de Morsier, G.,
370

dissociative anesthetic,
142

cortical dysgenesis hypothesis,
94

demyelinating disease and psychosis

DNA microarray studies,
297

cortical excitation/inhibition

multiple sclerosis,
274–
7

dopamine,
106,
134–
5

imbalance,
94–
5

Alberta study,
274–
5,
276

Davison and Bagley’s review,
274,

dopamine D2 receptor,
66–
7,
143,
182,

corticosteroids, as cause of toxic

275,
276

339

psychosis,
182

etiology,
276–
7

dorsal stream,
25

creatine, and Huntington’s Disease,

genetic links,
276

353

MRI brain changes,
276–
7

dorsolateral prefrontal cortex

outcomes,
277

(DLPFC),
5

Cummings, J.,
22,
265

treatment,
277

droperidol,
145

Curran, C.,
131

antipsychotic medication,
277

DSM diagnostic criteria, for psychosis,

Cutting, J.,
22–
3,
191

viral hypothesis,
276

264

cycloid psychosis,
329

multiple sclerosis, and psychosis,

DSM-III diagnostic criteria

cystamine, and Huntington’s Disease,

274–
7

brief reactive psychosis,
381

353

age of presentation,
275

six-month criterion for

clinical features,
275

schizophrenia,
80

cytokines,
282–
3

distinguishing characteristics,

DSM-III-R diagnostic criteria

275–
6

organic hallucinosis,
198

D1-like dopamine receptors,
118

gender ratio,
275–
6

on substance-induced psychosis,

D2-like dopamine receptors,
119,

organic psychosis,
275

113

134

prevalence,
274–
5

summary,
277

DSM-IV diagnostic criteria

D3-like dopamine receptors,
118

temporal association,
275

on brief psychotic disorder,
381,
382

Daly, D.,
32–
3,
265

taxonomy of demyelinating disease,

delirium,
179–
80

273

on delirium,
82,
179

Das, S. K.,
384

on personality disorder,
349

Dening, T. R.,
340

datura,
27

on post-stroke psychosis,
198

depression,
258

on psychosis,
113

David, A.,
21

and brain tumors,
266

on schizophrenia,
289

Davies, D. L.,
333,
334

and Fahr’s Disease,
360

on SLP associated with epilepsy,
81

DSM-IV diagnostic criteria (cont.)

environmental factors,
8f

definition issues,
80

on substance-induced psychosis,

Epidemiological Catchment Area

epilepsy/SLP affinity,
81

113

(ECA),
34,
170

epilepsy type determination,
81

on traumatic brain injury,
187,
191

forced normalization and,
88

epilepsy,
30

D’Souza, D. C.,
174

future directions,
95–
6

infantile myoclonic,
230

heterogeneity problem,
80

Durr, A.,
332

relationship with traumatic brain

ictal psychosis,
81–
3

dynamometer testing,
48

injury,
192–
3
See also
partial complex status,
81–
2

chronic interictal psychoses;

petit mal status,
82

dysarthria,
333

epilepsy, and schizophrenia-

seizures,
82–
3

disconnection syndrome,

like psychosis (SLP)

simple partial status,
82

schizophrenia as,
62–
3

epilepsy, and schizophrenia-like

postictal psychosis,
83–
5, 85t

brief interictal psychosis as

dysgraphesthesia, lateralizing,
53

psychosis (SLP)

anticonvulsant drugs,
87

distinct from,
88

dysphagia,
349

antipsychotic drugs,
87, 87t
,
changes in cerebral blood flow,

88

85

early development model, in

brief interictal psychosis,
86–
7

duration,
83–
4

schizophrenia,
8–
9

postictal psychosis as distinct

homeostatic mechanisms,
84–
5

from,
88

pathogenetic mechanisms,
84

eating disorders,
32

categorization of,
81, 81t

predisposing factors,
84

ecologic studies, on infections and

chronic interictal psychoses,
88–
95

treatment,
83–
4

schizophrenia,
279–
80

chronic SLP with epilepsy risk

seizure focus,
80–
1

superficial similarity,
80

Ecstasy (MDMA)

factors,
89–
91

temporal lobe epilepsy,
80

effects of,
148,
149

clinical features,
88–
9

illicit use of,
148–
9

evidence for schizophrenia/